Eurosurv. Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October

[tetano]

• C Henri van Werkhoven[SUP]1,2[/SUP] , Anne-Wil Valk[SUP]1[/SUP] , Bente Smagge[SUP]1[/SUP] , Hester E de Melker[SUP]1[/SUP] , Mirjam J Knol[SUP]1[/SUP] , Susan JM Hahné[SUP]1[/SUP] , Susan van den Hof[SUP]1[/SUP] , Brechje de Gier[SUP]1[/SUP]

We present early vaccine effectiveness (VE) estimates of the 2023 seasonal COVID-19 XBB.1.5 vaccine against COVID-19 hospitalisation and admission to an intensive care unit (ICU) in previously vaccinated adults ≥ 60 years in the Netherlands. We compared vaccination status of 2,050 hospitalisations including 92 ICU admissions with age group-, sex-, region- and date-specific population vaccination coverage between 9 October and 5 December 2023. VE against hospitalisation was 70.7% (95% CI: 66.6–74.3), VE against ICU admission was 73.3% (95% CI: 42.2–87.6).
​

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.1.2300703

​